Citations

Showing 10 of 108119 citations.

Comparison of hematopoietic progenitor cell collection using different inlet flow rates with the Fenwal Amicus
Burgstaler, Edwin A. , Bryant, Sandra C. , Winters, Jeffrey L.

Mayo Clinic

Journal of Clinical Apheresis | January 12, 2022 | Volume: 37 | Issue: 3 | Pages: 206-216

10.1002/jca.21959 | PMID 35018671 Get It

AbstractPurposeWe have used a hematopoietic progenitor cell (HPC) algorithm (standard [STD]) that restricted the inlet flow rate to 65 mL/min for peripheral white blood cell count (PWBC) >35 × 109/L (STD). In this study, we evaluated a technique that allows 85 mL/min, regardless of the PWBC count (high). For patients with PWBC >35 × 109/L, a prospective, randomized comparison of the high flow rate vs the STD PWBC‐based flow rate (65 mL/min) was performed, comparing CD34+ and lymphocyte yields, collection efficiencies (CE1), mononuclear cells (MNC), and granulocytes, red blood cell (RBC), and platelet content.MethodsThe Fenwal Amicus version 4.5 with a heparinized ACD‐A anticoagulant (AC) delivered at a 26:1 AC ratio was used. Paired comparisons between high and STD techniques were assessed with Wilcoxon signed rank tests, with P < .05 considered significant. Data are summarized as medians.ResultsForty patient pairs (autologous) were compared. Diagnoses included primarily multiple myeloma (60%) and lymphoma (37.5%). High had significantly higher median average inlet rates (69 vs 55 mL/min), whole blood processed (20 vs 16 L), and cycles (15 vs 14) than STD. There were no significant differences in pre‐procedure counts. Collection contents were (high/STD): 306/328 × 106 CD34+ cells, 48/59% CD34+ CE1 (significant), 0.2/0.2 × 109/kg lymphocytes, 45/57% lymphocyte CE1, 63/59 × 109 WBC, 15/16 × 109 granulocytes, and 1.9/1.7 × 1011 platelets.ConclusionsThe simpler, standardized high flow technique did not significantly increase or decrease CD34+ cells or lymphocyte yields, but did significantly decrease CD34+ CE1. The effects on cross‐cellular content were minimal and not clinically significant.
A Systematic Review of Nutritional Lab Correlates with Chemotherapy Induced Peripheral Neuropathy
Tofthagen, Cindy , Tanay, Mary Anne , Starr, Jason S. , Advani, Pooja , Sheffield, Katharine, Brigham, Tara , Perlman, Adam , Brigham, T J , Tofthagen, Cindy S

Mayo Clinic

Journal of Clinical Medicine | January 12, 2022 | Volume: 11 | Issue: 2 | Pages: 355

10.3390/jcm11020355 | PMID 35054049 Get It

Chemotherapy induced peripheral neuropathy (CIPN) is a dose-limiting side effect of chemotherapy for which no prevention or cure exists. Cancer and cancer treatments can adversely affect nutritional status. Nutrition may play a role in development of CIPN, yet the relationship between nutrition and CIPN is not well understood. Common laboratory values measuring various aspects of nutrition (hemoglobin/hematocrit, vitamin B12, calcium, and magnesium) may be associated with CIPN. The aim of this systematic review is to evaluate the empirical evidence surrounding the relationship between laboratory measures of nutrition and CIPN among persons with cancer who received neurotoxic chemotherapy drugs. We conducted an extensive review of the literature to identify articles that evaluated relationships between laboratory measures of nutrition and CIPN. A total of eleven articles satisfied the inclusion/exclusion criteria. Participants in the studies had breast or colorectal cancer, lymphoma or multiple myeloma and were receiving a variety of neurotoxic drugs. Hemoglobin/hematocrit, vitamin D, albumin, and magnesium were associated with CIPN. The quality of the studies ranges from fair to good. Evidence suggests that low levels of the above-mentioned tests could be associated with CIPN but additional research is needed.
CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival
Minguillón, Jordi , Ramı́rez, Marı́a José , Rovirosa, Llorenç , Bustamante‐Madrid, Pilar , Camps-Fajol, Cristina, Garibay, Gorka Ruíz de , Montanuy, Helena, Pujol, Roser, Hernández, Gonzalo , Bosch, Pau Castillo , Soucy, Penny, Martrat, Griselda, Gómez, Antonio , Cuadras, Daniel , García, María J. , Gayarre, Javier Machín , CIMBA, Pujana, Miguel Ángel , Surrallés, Jordi , Ruiz de Garibay, Gorka , Shimelis, Hermela , Hernandez, Gonzalo , Gómez, Antonio , Cuadras, Daniel , Pujana, Miquel Angel , Surrallés, Jordi , Bogliolo, Massimo , Gayarre, Javier, CIMBA, Lázaro, Conxi , Benı́tez, Javier , Couch, Fergus J.

Mayo Clinic

Cancers | January 12, 2022 | Volume: 14 | Issue: 2 | Pages: 353

10.3390/cancers14020353 | PMID 35053516 Get It

BRCA2 is essential for homologous recombination DNA repair. BRCA2 mutations lead to genome instability and increased risk of breast and ovarian cancer. Similarly, mutations in BRCA2-interacting proteins are also known to modulate sensitivity to DNA damage agents and are established cancer risk factors. Here we identify the tumor suppressor CDK5RAP3 as a novel BRCA2 helical domain-interacting protein. CDK5RAP3 depletion induced DNA damage resistance, homologous recombination and single-strand annealing upregulation, and reduced spontaneous and DNA damage-induced genomic instability, suggesting that CDK5RAP3 negatively regulates double-strand break repair in the S-phase. Consistent with this cellular phenotype, analysis of transcriptomic data revealed an association between low CDK5RAP3 tumor expression and poor survival of breast cancer patients. Finally, we identified common genetic variations in the CDK5RAP3 locus as potentially associated with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Our results uncover CDK5RAP3 as a critical player in DNA repair and breast cancer outcomes.
Sport-Related Concussion Preceding Adrenal Insufficiency and Hypopituitarism
Northam, Weston T. , Carneiro, Kevin A., Alexander, Andrew

Mayo Clinic

Current Sports Medicine Reports | January 12, 2022 | Volume: 21 | Issue: 1 | Pages: 15-17

10.1249/jsr.0000000000000926 | PMID 35018894 Get It

Abstract A 49-year-old woman with a history of daily inhaled corticosteroid use for asthma presented to a concussion clinic 7 wk after sport-related head injury with headache, visual blurring, dizziness, nausea, fatigue, polydipsia, and polyuria. Examination revealed difficulty with vestibulo-occulomotor testing due to nausea and visual straining. Cranial CT/MR imaging was unremarkable. Laboratory testing revealed critically low serum cortisol, hypernatremia, and urine studies suggesting diabetes insipidus. The patient was referred to the emergency department. Intravenous fluid resuscitation, corticosteroids, and desmopressin led to significant symptomatic relief. She was maintained on oral hydrocortisone after cosyntropin test revealed adrenal insufficiency. Her clinical picture suggested chronic subclinical adrenal suppression from inhaled corticosteroids, which was exacerbated by hypopituitarism possibly from concussion combined with diabetes insipidus. Adrenal insufficiency should be considered in athletes with history of corticosteroid use and endocrine-related symptoms after concussion, because this can create significant morbidity and can mimic traditional symptoms of concussion.
Complications Based on Prostate Size After Plasmakinetic Enucleation of the Prostate
Mian, Abrar , Balzano, Felicia, Pachorek, Mark, Sam, Andre‐Philippe , Warner, Jonathan N. , Balzano, Felicia L, Mian, Abrar H , Ruel, Nora H.

Mayo Clinic

Journal of Endourology | January 12, 2022 | Volume: 36 | Issue: 7 | Pages: 969-976

10.1089/end.2021.0911 | PMID 35018807 Get It

Purpose: Lower urinary tract symptoms among adult men can significantly impact quality of life. We evaluated complications based on prostate size following plasmakinetic enucleation of the prostate. Materials and Methods: Patients were grouped into the small prostate group (SPG, <75 g) and large prostate group (LPG, >75 g) based on preoperative imaging. Patient data on demographics, comorbidities, preoperative international prostate symptom score (IPSS), bother index (BI), prostate-specific antigen (PSA) if indicated, postvoid residual volume (PVR), indwelling catheter or self-catheterization status, and any prior surgical intervention were evaluated. Postoperative IPSS, BI, and PVR values were assessed at 6 weeks, 4 months, and yearly. Postoperative urge urinary incontinence (UUI), stress urinary incontinence (SUI), and pad use were assessed. Results: Between September 2015 and December 2020, 296 patients who underwent bipolar enucleation with minimum follow-up of 4 months were evaluated. Postoperative IPSS, BI, PVR, and PSA values at all time points were significantly decreased compared with preoperative values ( p < 0.05). There was no significant difference in the complications between groups. Univariable and multivariable analysis found that size <75 g was predictive of stricture formation and bladder neck contracture (BNC). UUI was more common at 6 weeks in the SPG, and SUI was more common at 6 weeks in the LPG, but no difference was noted at the 4-month and 1-year time points. Pad use was equal between the two groups at all time points. Conclusions: Plasmakinetic enucleation of the prostate provides an effective treatment option for prostates of all sizes; however, prostates <75 g have a higher rate of BNC and urethral strictures compared with those >75 g.
Simultaneous dual‐contrast imaging using energy‐integrating detector multi‐energy CT: An in vivo feasibility study
Zhou, Zhongxing , Ren, Liqiang , Yu, Lifeng , Diehn, Felix E. , Rajendran, Kishore , Fletcher, Joel G. , McCollough, Cynthia H. , Yu, Lifeng

Mayo Clinic

Medical Physics | January 12, 2022 | Volume: 49 | Issue: 3 | Pages: 1458-1467

10.1002/mp.15448 | PMID 35018658 Get It

AbstractPurposeTo demonstrate the feasibility of simultaneous dual‐contrast imaging in a large animal using a newly developed dual‐source energy‐integrating detector (EID)‐based multi‐energy computed tomography (MECT) system.MethodsTwo imaging tasks that may have potential clinical applications were investigated: head/neck (HN) CT angiography (CTA)/CT venography (CTV) with iodine and gadolinium, and small bowel imaging with iodine and bismuth in domestic swine. Dual‐source X‐ray beam configurations of 70 kV + Au120/Sn120 kV and 70 kV + Au140/Sn140 kV were used for the HN‐CTA/CTV and small bowel imaging studies, respectively. A test bolus scan was performed for each study. The regions of interest (ROIs) in the carotid artery and jugular vein for HN‐CTA/CTV imaging and abdominal aorta for small bowel imaging were used to determine the time‐attenuation curves, based on which the timing for contrast injection and the CT scan was determined. In the HN‐CTA/CTV study, an MECT scan was performed at the time point corresponding to the optimal arterial enhancement by iodine and the optimal venous enhancement by gadolinium. In the small bowel imaging study, an MECT scan was performed at the optimal time point to simultaneously capture the mesenteric arterial enhancement of iodine and the enteric enhancement of bismuth. Image‐based material decomposition was performed to decompose different materials for each study. To quantitatively characterize contrast material separation and misclassification, two ROIs on left common carotid artery and left internal jugular vein in HN‐CTA/CTV imaging and three ROIs on superior mesenteric artery, ileal lumen, and collapsed ileum (ileal wall) in small bowel imaging were placed to measure the mean concentration values and the standard deviations.ResultsIn the HN‐CTA/CTV study, common carotid arteries containing iodine and internal/external jugular veins containing gadolinium were clearly delineated from each other. Fine vessels such as cephalic veins and branches of external jugular veins were noticeable but clear visualization was hindered by image noise in gadolinium‐specific (CTV) images, as reviewed by a neuroradiologist. In the small bowel imaging study, the mesenteric arteries and collapsed bowel wall containing iodine and the small bowel loops containing bismuth were clearly distinctive from each other in the iodine‐ and bismuth‐specific images after material decomposition, as reviewed by an abdominal radiologist. Quantitative analyses showed that the misclassifications between the two contrast materials were less than 1.7 and 0.1 mg/ml for CTA/CTV and small bowel imaging studies, respectively.ConclusionsFeasibility of simultaneous CTA/CTV imaging in head and neck with iodine and gadolinium and simultaneous imaging of arterial and enteric phases of small bowel with iodine and bismuth, using a dual‐source EID‐MECT system, was demonstrated in a swine study. Compared to iodine and gadolinium in CTA/CTV, better delineation and classification of iodine and bismuth in small bowel imaging were achieved mainly due to wider separation between the corresponding two K‐edge energies.
Temporal trends and in‐hospital complications of catheter ablation for atrial fibrillation among patients with moderate and advanced chronic kidney diseases: 2005−2018
Prasitlumkum, Narut , Chokesuwattanaskul, Ronpichai , Kaewput, Wisit , Tokavanich, Nithi , Cheungpasitporn, Wisit , Vallabhajosyula, Saraschandra , Jongnarangsin, Krit, Cheungpasitporn, Wisit , Kaewput, Wisit , Chokesuwattanaskul, Ronpichai , Vallabhajosyula, Saraschandra , Prasitlumkum, Narut , Thongprayoon, Charat , Boonpheng, Boonphiphop

Mayo Clinic

Journal of Cardiovascular Electrophysiology | January 12, 2022 | Volume: 33 | Issue: 3 | Pages: 401-411

10.1111/jce.15354 | PMID 35018675 Get It

AbstractIntroductionReal‐world data on atrial fibrillation (AF) ablation among moderate and advanced chronic kidney disease (CKD) patients have so far remained scarce, especially in‐hospital AF ablation outcomes.MethodsWe drew data from the US National Inpatient Sample to identify hospitalized patients who underwent AF ablation between 2005 and 2018, and further stratified by CKD classification. We assessed the trend of AF ablation, as well as its complications.ResultsA total of 152 630 patients who were primarily hospitalized for AF and underwent ablation were estimated. Among these, CKD patients were found in a total of 1509 participants, with 978, 206, and 325 under CKD3, CKD4, and CKD5/ESKD, respectively. There was a significant increment in admission rates for AF ablation in the CKD population across all CKD classifications (p < .001). All CKD patients were statistically older, with higher coexisting comorbidities, while hypertension was found substantially lower than non‐CKD patients (p ≤ .001). Importantly, CKD, especially CKD3 and CKD5/ESKD, was significantly associated with an increased risk of total complications, and total bleeding, Neurological complications were found statistically lower in CKD patients (p = .029), and no mortality rates were significantly different (p = .287).ConclusionOur study observed an increase in admission trends for AF ablation among moderate and advanced CKD patients from 2005 to 2018. CKD was strongly associated with higher procedure‐related complications and bleeding, but neurological safety profiles and mortalities rates were nonsignificantly different.
Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum
Godara, Amandeep, Wang, Andy Y., Arkun, Knarik, Fogaren, Teresa, Qamar, Adnan S., McPhail, Ellen D., Kryzanski, James, Riesenburger, Ron, Comenzo, Raymond, Godara, Amandeep, Wang, Andy Y., Arkun, Knarik, Fogaren, Teresa, Qamar, Adnan S., McPhail, Ellen D., Kryzanski, James, Riesenburger, Ron, Comenzo, Raymond

Mayo Clinic

Surgical Neurology International | January 12, 2022 | Volume: 13 | Issue: No issue available | Pages: 12

10.25259/sni_1235_2021 | PMID 35127212 Get It

Background: Amyloidosis is a protein misfolding disorder that leads to the deposition of beta-pleated sheets of a fibrillar derivative of various protein precursors. Identification of the type of precursor protein is integral in treatment decision-making. The presence of two different types of amyloid in the same patient is unusually rare, and there are no previous reports of two different types of amyloid deposition in the ligamentum flavum (LF) in the same patient. Case Description: Here, we describe two patients with spinal stenosis who underwent laminectomies and were found to have AL and ATTR amyloid deposits in the LF. Conclusion: As the spine is becoming recognized as a site for ATTRwt amyloid deposition, patients undergoing spinal decompression surgery may potentially benefit from evaluation for amyloidosis in the LF.
Hospital Frailty Risk Score and Healthcare Resource Utilization After Surgery for Primary Spinal Intradural/Cord Tumors
Elsamadicy, Aladine A. , Reeves, Benjamin C. , Pennington, Zach , Sarkozy, Margot , Hersh, Andrew M. , Sherman, Josiah , Goodwin, C. Rory , Kolb, Luis, Laurans, Maxwell , Lo, Sheng-Fu Larry , Sciubba, Daniel M. , Pennington, Zach , Hersh, Andrew , Goodwin, C Rory , Sciubba, Daniel , Koo, Andrew B. , Havlik, John, Shin, John H.

Mayo Clinic

Global Spine Journal | January 11, 2022 | Volume: 13 | Issue: 7 | Pages: 2074-2084

10.1177/21925682211069937 | PMID 35016582 Get It

Objective The Hospital Frailty Risk Score (HFRS) is a metric that measures frailty among patients in large national datasets using ICD-10 codes. While other metrics have been utilized to demonstrate the association between frailty and poor outcomes in spine oncology, none have examined the HFRS. The aim of this study was to investigate the impact of frailty using the HFRS on complications, length of stay, cost of admission, and discharge disposition in patients undergoing surgery for primary tumors of the spinal cord and meninges. Methods A retrospective cohort study was performed using the Nationwide Inpatient Sample database from 2016 to 2018. Adult patients undergoing surgery for primary tumors of the spinal cord and meninges were identified using ICD-10-CM codes. Patients were categorized into 2 cohorts based on HFRS score: Non-Frail (HFRS<5) and Frail (HFRS≥5). Patient characteristics, treatment, perioperative complications, LOS, discharge disposition, and cost of admission were assessed. Results Of the 5955 patients identified, 1260 (21.2%) were Frail. On average, the Frail cohort was nearly 8 years older ( P < .001) and experienced more postoperative complications ( P = .001). The Frail cohort experienced longer LOS ( P < .001), a higher rate of non-routine discharge ( P = .001), and a greater mean cost of admission ( P < .001). Frailty was found to be an independent predictor of extended LOS ( P < .001) and non-routine discharge ( P < .001). Conclusion Our study is the first to use the HFRS to assess the impact of frailty on patients with primary spinal tumors. We found that frailty was associated with prolonged LOS, non-routine discharge, and increased hospital costs.
Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasis
Perou, Charles M. , Hinoue4, Toshinori, Wheeler, Gregory , Kelly, Benjamin , Garrido-Castro, Ana C. , Cubas, Aguirre De, Rajkovic, Andrei, Karaesmen, Ezgi , Fan, Cheng, Creighton, Chad J. , Leraas, Kristen , Burns, Robyn, Coppens, Sara E. , Wheless, Amy, Rezk, Salma, Garrett, Amy, Foy, Kelly K. , Park, Ben, Krop, Ian E. , Anders, Carey K. , Rimawi, Mothaffar F. , Nanda, Rita , Storniolo, Anna Maria , Chandran, Uma , Davis, Michael J. , Ropelewski, Alexander J. , Liu, Minetta C. , Richardson, Andrea L. , Symmans, W. Fraser , Davidson, Nancy E. , King, Tari A. , Perou, Charles M , Rimawi, Mothaffar , Symmans, W Fraser , García‐Recio, Susana , Hinoue4, Toshinori, Pascual, Tomás , Xia, Youli , McClure, Marni B. , Smith, Markia A. , Fan, Cheng, Bowen, Jay , Parker, Joel S. , Shen, Hui , Gastier‐Foster, Julie M. , Lin, Nancy U. , Isaacs, Claudine , Marcom, Paul Kelly , Couch, Fergus J. , Silverstein, Jonathan C. , Hilsenbeck, Susan Galloway , Norton, Larry , Wolff, Antonio C. , Carey, Lisa A. , Lee, Adrian V. , Balko, Justin M. , Hoadley, Katherine A. , Laird, Peter W. , Mardis, Elaine R.

Mayo Clinic

No container title available | January 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1221704/v1 Get It

Abstract Patients with metastatic breast cancer (MBC) typically have short survival times and their successful treatment represents one of most challenging aspects of patient care. This poor prognostic behavior is in part due to molecular features including increased tumor cell clonal heterogeneity, multiple drug resistance mechanisms, and alterations of the tumor microenvironment. The AURORA US Metastasis Project was established with the goal to identify molecular features specifically associated with metastasis. We therefore collected and molecularly characterized specimens from 55 metastatic breast cancer (BC) patients representing 51 primary cancers and 102 metastases. The 153 unique tumors were assayed using RNAseq, tumor/germline DNA exomes and low pass whole genome sequencing, and global DNA methylation microarrays. We found intrinsic molecular subtype differences between primary tumors and their matched metastases to be rare in triple negative breast cancer (TNBC)/Basal-like subtype tumors. Conversely, tumor subtype changes were relatively frequent in estrogen receptor positive (ER+) cancers where ~30% of Luminal A cases switched to Luminal B or HER2-enriched (HER2E) subtypes. Clonal evolution studies identified changes in expression subtype coincident with DNA clonality shifts, especially involving HER2 amplification and/or the HER2E expression subtype. We further found evidence for ER-mediated downregulation of genes involved in cell-cell adhesion in metastases. Microenvironment differences varied according to tumor subtype where ER+/Luminal metastases had lower fibroblast and endothelial cell content, while TNBC/Basal-like metastases showed a dramatic decrease in B cells and T cells. In 17% of metastatic tumors, we identified DNA hypermethylation and/or focal DNA deletions near HLA-A that were associated with its’ significantly reduced expression, and with lower immune cell infiltrates. We also identified low immune cell features in brain and liver metastases when compared to other metastatic sites, even within the same patient. These findings have direct implications for the treatment of metastatic breast cancer patients with immune- and HER2-targeting therapies and suggest potential novel therapeutic avenues for the improvement of outcomes for some patients with MBC.